HOUSTON, TX, Indapta Therapeutics announced today it has closed a $22.5 million round of new financing.
Indapta Therapeutics, a privately held clinical stage biotechnology company developing next-generation cell therapies for the treatment of cancer and autoimmune diseases, announced today it has closed a $22.5 million round of new financing to accelerate the clinical development of its differentiated allogeneic Natural Killer (NK) cell therapy. Current investors RA Capital Management, LP, Leaps by Bayer, the impact investment arm of Bayer AG, Vertex Ventures HC, Pontifax, and the Myeloma Investment Fund, the venture philanthropy subsidiary of the Multiple Myeloma Research Foundation, completed the round.
Indapta is a privately-held company focused on developing and bringing to market a diverse pipeline of cell…
Read Full Article at: VC News Daily